Bausch and Lomb has launched PreserVision AREDS3 eye vitamins in the United States.
The supplement retains the full AREDS2 formula – lutein, zeaxanthin, vitamins C and E, and zinc – and adds a B-vitamin complex comprising thiamin (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), vitamin B6, biotin (B7), folate (B9), and vitamin B12.1
Bausch and Lomb said the addition of the B-vitamins was informed by a narrative review published in Ophthalmology and Therapy in December last year, which synthesised findings from more than 20 human studies involving approximately 30,000 individuals.² The review cited evidence from large randomised clinical trials, finding a statistically significant association between specific B-vitamin supplementation and reduced risk of age-related macular degeneration (AMD).
The company said the formulation achieves two-times greater absorption of lutein and zeaxanthin compared to the original PreserVision AREDS2 formula.
The product is not available in Australia or New Zealand.
The company said the formulation achieves two-times greater absorption of lutein and zeaxanthin compared to the original PreserVision AREDS2 formula.
References
- Bausch + Lomb, Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the United States, media release 19 May 2026, available at: businesswire.com/news/home/20260519610457/en/Bausch-Lomb-Launches-PreserVision-AREDS3-Eye-Vitamins-in-the-United-States [accessed May 2026].
- Poteet J, Koetting C, Vakharia PS. Role of B vitamins in preventing the development and progression of age-related macular degeneration. Ophthalmol Ther. 2026;15:1-19 doi: 10.1007/s40123-025-01281-1.
